By Chris Wack
MediciNova shares were up 14% to $2.30 after the company reported positive data for its phase 2 clinical trial of MN-166 ibudilast in glioblastoma patients.
The stock hit its 52-week low of $1.71 on Thursday, and is down 3% in the past 12 months.
The…
Master your money.
Subscribe to MarketWatch.
Get this article and all of MarketWatch.
Access from any device. Anywhere. Anytime.
Subscribe Now
Already a subscriber?
Log In
Read the full article here
